Trial Outcomes & Findings for The Use of Heliox in Obstructive Sleep Apnea Syndrome (NCT NCT02135900)

NCT ID: NCT02135900

Last Updated: 2015-06-01

Results Overview

Assessment of Apnea/Hypopnea Index (AHI) at baseline ( without heliox) and after 6-8 hours of sleep with heliox.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

32 participants

Primary outcome timeframe

Baseline and in 6-8 hours. The reported data are at baseline ( without heliox) and after 6-8 hours of sleep with heliox.

Results posted on

2015-06-01

Participant Flow

Participant milestones

Participant milestones
Measure
Heliox
Heliox which is a mix of oxygen and helium gase will be administered through a face mask during part of the sleep study. Heliox: From the onset of sleep until 2:00 am, patients will be placed on heliox 70/30. At 2:00 am patients will be switched to CPAP for titration according to American Academy of Sleep Medicine (AASM) guidelines.
Overall Study
STARTED
32
Overall Study
COMPLETED
32
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

The Use of Heliox in Obstructive Sleep Apnea Syndrome

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Heliox
n=32 Participants
Heliox which is a mix of oxygen and helium gase will be administered through a face mask during part of the sleep study. Heliox: From the onset of sleep until 2:00 am, patients will be placed on heliox 70/30. At 2:00 am patients will be switched to CPAP for titration according to American Academy of Sleep Medicine (AASM) guidelines.
Age, Categorical
<=18 years
0 Participants
n=39 Participants
Age, Categorical
Between 18 and 65 years
23 Participants
n=39 Participants
Age, Categorical
>=65 years
9 Participants
n=39 Participants
Age, Continuous
52 years
STANDARD_DEVIATION 7 • n=39 Participants
Sex: Female, Male
Female
9 Participants
n=39 Participants
Sex: Female, Male
Male
23 Participants
n=39 Participants
Region of Enrollment
United States
32 participants
n=39 Participants

PRIMARY outcome

Timeframe: Baseline and in 6-8 hours. The reported data are at baseline ( without heliox) and after 6-8 hours of sleep with heliox.

Population: Subjects with documented sleep apnea syndrome on nocturnal polysomnography

Assessment of Apnea/Hypopnea Index (AHI) at baseline ( without heliox) and after 6-8 hours of sleep with heliox.

Outcome measures

Outcome measures
Measure
Heliox
n=30 Participants
Heliox which is a mix of oxygen and helium gase will be administered through a face mask during part of the sleep study. Heliox: From the onset of sleep until 2:00 am, patients will be placed on heliox 70/30. At 2:00 am patients will be switched to CPAP for titration according to American Academy of Sleep Medicine (AASM) guidelines.
Apnea Hypopnea Index
At baseline ( without Heliox)
42.71 Apneas or hypopneas per hour sleep
Interval 33.16 to 52.25
Apnea Hypopnea Index
after 6-8 hours ( with Heliox)
40.95 Apneas or hypopneas per hour sleep
Interval 32.68 to 49.23

PRIMARY outcome

Timeframe: Baseline and in 6-8 hours. The reported data are at baseline ( without heliox) and after 6-8 hours of sleep with heliox.

Population: Subjects with documented sleep apnea syndrome on nocturnal polysomnography

Assessment of Apnea Index (AI) at baseline ( without heliox) and after 6-8 hours of sleep with heliox.

Outcome measures

Outcome measures
Measure
Heliox
n=30 Participants
Heliox which is a mix of oxygen and helium gase will be administered through a face mask during part of the sleep study. Heliox: From the onset of sleep until 2:00 am, patients will be placed on heliox 70/30. At 2:00 am patients will be switched to CPAP for titration according to American Academy of Sleep Medicine (AASM) guidelines.
Apnea Index (AI)
At baseline ( without Heliox)
16.46 Number of apneas per hour sleep
Interval 7.59 to 25.33
Apnea Index (AI)
after 6-8 hours ( with Heliox)
11.26 Number of apneas per hour sleep
Interval 4.98 to 17.53

PRIMARY outcome

Timeframe: Baseline and in 6-8 hours.

Population: Subjects with documented sleep apnea syndrome on nocturnal polysomnography

Assessment of L SO2 at baseline ( without heliox) and after 6-8 hours of sleep with heliox.

Outcome measures

Outcome measures
Measure
Heliox
n=30 Participants
Heliox which is a mix of oxygen and helium gase will be administered through a face mask during part of the sleep study. Heliox: From the onset of sleep until 2:00 am, patients will be placed on heliox 70/30. At 2:00 am patients will be switched to CPAP for titration according to American Academy of Sleep Medicine (AASM) guidelines.
Lowest Oxygen Saturation (L SO2)
At baseline ( without Heliox)
84.22 Percentage of oxygen saturation
Interval 82.07 to 86.38
Lowest Oxygen Saturation (L SO2)
after 6-8 hours ( with Heliox)
90.47 Percentage of oxygen saturation
Interval 88.71 to 92.23

PRIMARY outcome

Timeframe: Baseline and in 6-8 hours.

Population: Subjects with documented sleep apnea syndrome on nocturnal polysomnography

Assessment of M SO2 at baseline ( without heliox) and after 6-8 hours of sleep with heliox.

Outcome measures

Outcome measures
Measure
Heliox
n=30 Participants
Heliox which is a mix of oxygen and helium gase will be administered through a face mask during part of the sleep study. Heliox: From the onset of sleep until 2:00 am, patients will be placed on heliox 70/30. At 2:00 am patients will be switched to CPAP for titration according to American Academy of Sleep Medicine (AASM) guidelines.
Mean Oxygen Saturation (M SO2)
At baseline ( without Heliox)
93.47 Percentage of oxygen saturation
Interval 92.5 to 94.43
Mean Oxygen Saturation (M SO2)
after 6-8 hours ( with Heliox)
96.29 Percentage of oxygen saturation
Interval 95.51 to 97.07

Adverse Events

Heliox

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Michel Chalhoub, MD

Staten Island University Hospital

Phone: 7182269000

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place